Commercialization: Page 24

PharmaVoice Team/PharmaVoice

Last Word

Combating Opioid Addiction Sarah Akerman, M.D., Senior Medical Director at Alkermes, talks about the industry’s role in opioid use disorder. PV: What are some of the biggest issues around the current treatment system for addiction? Akerman: The current treatment system for opioid addiction is ina...
By Sarah Akerman • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Artificial Intelligence: Molecule to Market

The adoption of artificial intelligence (AI) is rapidly taking hold across global businesses, including the life-sciences industry. AI is typically defined as the ability of a machine to perform cognitive functions associated with human minds, such as perceiving, reasoning, learning, and problem ...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

SHOWCASE: Social Media: A Strategic Approach: Key to Social Media Success

Data from the second quarter of 2018 show that Facebook had 2.23 billion monthly active users, while Twitter had 326 million active users in the third quarter of 2018. Consumers use social media for many reasons today, including to learn about a medicine or illness. The use of social media forums...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

2019 Social Media Trends for Pharma

In a relatively short period of time, social media has reshaped communication for consumers and healthcare professionals alike. No longer are users simply posting content and communicating amongst themselves — social channels are now dominated by media reaching specifically targeted audiences. Lo...
By Brandie Linfante • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Drug Pricing Transparency: Will it be Now or Never?

In the ongoing clash between pharma and the Trump administration over pricing issues, CMS proposed a rule last year that would require pharmaceutical companies to include the price of any drug that cost more than $35 a month in their television ads. PhRMA preempted the salvo with a voluntary pled...
By Robin Robinson • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Red Zone: To Gain Competitive Advantage, Learn Your ABCDs

Understanding and staying engaged with patients throughout their treatment and wellness journey is a primary focus of the entire life sciences industry. The benefits are clear: • Patients’ trust in the therapy and its ecosystem grows • Longitudinal data on patient progress provides evidence for v...
By Sriraman Nagarajan • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Letter from the Editor

The year ahead… As we come to the end of 2018, it’s important to pause and reflect on not just where we’ve been, but where we are going as an industry. In 2018, we saw continuing uncertainty in terms of the Affordable Care Act. We welcomed Alex Azar as the new Secretary of Health and Human Servic...
By Taren Grom • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Last Word

In Her Shoes: Understanding the Female Patient Experience Elizabeth Bolgiano, Executive VP, Chief Human Resources Officer at AMAG Pharmaceuticals, discusses the company’s efforts to imagine “walking a mile" in its female patients’ shoes as they seek care for sexual health-related conditions. PV: ...
By Elizabeth Bolgiano • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Advanced Diagnostics and Precision Medicine

Healthcare is moving increasingly toward personalized approaches — tailoring treatment based on each patient’s unique disease. Precision medicine is well-established in oncology, with many cancers now characterized by their unique genomic alterations. In the past few years, the Food and Drug Admi...
By PharmaVoice Team • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Creating Shared Value

Shared value was first introduced by Michael Porter and Marc Kramer in their Harvard Business Review article in 2011. Since then, multiple industries have assessed how to implement shared value into their business practices. In other industries, companies need to work hard to find a public good t...
By Taren Grom • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Genetic Testing and Data Privacy and Ownership

Genetic testing is a booming market. According to reports, as of April 2018 more than 15 million people had taken direct-to-consumer genetic tests, and with prices for autosomal DNA tests now costing less than $100, they have become very accessible. Companies such as 23andMe, Ancestry.com, and My...
By Kim Ribbink • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Innovative Product Launches

Increasing complexity in the market and pressure on managing costs already create many challenges when it comes to new drug launches. Add to that the intricacies of innovative and combination drugs and the speed at which they need to launch, and challenges multiply. However, this shifting environ...
By Robin Robinson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Multistakeholder Commercial Models

In the coming years, pharma will mobilize around engaging and accommodating a multitude of stakeholders to generate a competitive advantage. Long gone are the days of targeting healthcare providers as the entire commercial strategy. Simplicity in commercialization no longer exists and has been re...
By Robin Robinson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Rare Disease Innovation

It’s been almost 120 years since the word gene was coined. Today, researchers are well on their way to manipulating genes to treat diseases. With only about 400 approved treatments for more than 7,000 rare diseases — 80% of which are caused by gene mutations — scientific advances are enabling gen...
By PharmaVoice Team • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Voice Assistants

Alexa, how will voice assistants impact the pharmaceutical commercial landscape in the next five years? Alexa is “not sure about that," but our experts have the answers as smart speakers and voice technology begin to penetrate not only healthcare, but the pharma commercialization process as well....
By Robin Robinson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

SHOWCASE: eSolutions: Changing the Face of Patient Empowerment

With so many new players entering the realm of eSolutions to drive patient engagement and patient empowerment, life-sciences companies ignore digital innovation at their peril. What exactly are eSolutions in the context of healthcare delivery? Over the past few years, eSolutions have become more ...
By PharmaVoice Team • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

How Pharma Can Benefit From the EHR

The digital age has been making waves since the late 1900s and the electronic health record (EHR) industry is one small piece in a vast pool of digital channels available for pharmaceutical companies through which to message their brands. The EHR, or EMR (electronic medical record), has been an i...
By Kaitlyn Clark • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

If You Build It, Will They Come

A colleague of mine here at the agency shared a fascinating article in our Slack channel with this compelling quote: “I did not go to medical school to sit on my butt for four to six hours a day doing data entry in a computer…"1 I feel for this doctor. I recall the time when my general practice p...
By Rico Cipriaso • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Digital Media Gets Social: The Five W's

While traditionally slow to adopt new innovations across many sectors, pharmaceutical and healthcare organizations have become more immersed in mainstream culture and have evolved their promotional plans accordingly. Following the societal trend of digital dependency, industry spend towards commu...
By Elizabeth Hefner • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites

Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20% to 25% of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit" sites and returned to them for ...
By Seth Nelson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Upfront

BMS Participates in V Foundation for Cancer Research Bike Ride For the fifth year in a row, Bristol-Myers Squibb has launched the Coast 2 Coast 4 Cancer, a nearly month-long cross-country bike ride to raise money for cancer research. During the month of September, company employees ride nearly 3,...
By PharmaVoice Team • Oct. 1, 2018
PharmaVoice Team/PharmaVoice

HealthTech

Medisafe and Boehringer Ingelheim Partner to Support U.S. Pradaxa Patients Trend Watch: Pharma-backed digital health solutions improve patient care and adherence. Patient adherence app developer Medisafe is partnering with Boehringer Ingelheim to provide Pradaxa patients with educational materia...
By PharmaVoice Team • Oct. 1, 2018
PharmaVoice Team/PharmaVoice

Creating a Commercial Path for Innovative Medicines

We are in an era of unprecedented innovation. Gene and cancer immunotherapies, RNAi therapies, smart medicines and digital therapies, as well as a whole host of other innovative remedies still in the pipeline, are treating and even curing life-threatening diseases. But these innovations often com...
By Denise Myshko • Oct. 1, 2018
PharmaVoice Team/PharmaVoice

SHOWCASE: Patient Solutions: Connecting to the Patient in the Digital Age

Pharmaceutical companies are shifting their mindset away from simply selling to physicians and toward serving the patient. But a truly patient-centric approach requires more than developing drugs to treat disease; it also requires providing services and support that patients want and need to mana...
By PharmaVoice Team • Oct. 1, 2018
PharmaVoice Team/PharmaVoice

Enhancing Pharma's Patient Support Services

As experts in health-related behavior change and treatment adherence, we are often approached by pharma to augment existing patient support services for a brand or product portfolio. Many recognize the need for enhancement yet express concern about change, wanting to avoid any change that may be ...
By Kate Perry • Oct. 1, 2018